Please ensure Javascript is enabled for purposes of website accessibility

Foamix Pharmaceuticals Ltd Hopes to Profit From Eli Lilly's and Amgen's Side Effect

By Brian Orelli, PhD - Dec 3, 2015 at 1:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech gets pumped up on positive phase 2 data for FDX104.

What: Foamix Pharmaceuticals (FOMX) is up about 10% at 1:00 p.m. EST after releasing positive results from its phase 2 clinical study of FDX104.

So what: FDX104 is designed to prevent moderate-to-severe skin rashes in patients treated with the epidermal growth factor receptor antibody inhibitors (EGFRI), such as Eli Lilly's (LLY 1.25%) Erbitux and Amgen's (AMGN 0.62%) Vectibix. The rash, while not as life threatening as the cancer that Eli Lilly's and Amgen's drugs are designated to treat, can get so bad that doctors need to reduce the dose or even discontinue the treatment altogether.

Foamix Pharmaceuticals trial enrolled just 24 patients, but the data look fairly strong. The patients acted as their own controls, putting FDX104 on one side of their face and placebo on the other. The drug side only had severe rash in four out of the 24 patients while the placebo side had a severe rash in nine of the 24. The difference was statistically significant.

Now what: Foamix Pharmaceuticals needs to talk to the FDA to figure out how to proceed but will likely have to run a phase 3 program before getting FDX104 approved by regulators. Like all small phase 2 trials, the biggest risk is that the efficacy difference between FDX104 and placebo isn't seen in a larger trial. The phase 2 data could be a fluke, but we won't know until larger trials are run.

There's also the potential for side effects from FDX104 to be discovered when it's tested in more patients, but the active ingredient, doxycycline, is a common antibiotic that's sometime use as an oral off-label treatment for the rash, so it's probably a low risk.

Investors in Eli Lilly and Amgen should keep an eye on the development of FDX104 because the companies will obviously benefit if FDX104 can help keep patients on their drug longer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Foamix Pharmaceuticals Ltd. Stock Quote
Foamix Pharmaceuticals Ltd.
Amgen Inc. Stock Quote
Amgen Inc.
$249.04 (0.62%) $1.54
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$302.60 (1.25%) $3.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.